Small Molecule Screening in Human Induced Pluripotent Stem Cell-derived Terminal Cell Types |
| |
Authors: | Sandra J Engle Fabien Vincent |
| |
Institution: | From Pharmacokinetics, Dynamics and Metabolism–New Chemical Entities, Pfizer Inc., Groton, Connecticut 06340 |
| |
Abstract: | A need for better clinical outcomes has heightened interest in the use of physiologically relevant human cells in the drug discovery process. Patient-specific human induced pluripotent stem cells may offer a relevant, robust, scalable, and cost-effective model of human disease physiology. Small molecule high throughput screening in human induced pluripotent stem cell-derived cells with the intent of identifying novel therapeutic compounds is starting to influence the drug discovery process; however, the use of these cells presents many high throughput screening development challenges. This technology has the potential to transform the way drug discovery is performed. |
| |
Keywords: | Drug Action Drug Development Drug Discovery Drug Screening Stem Cells |
|
|